Neuphoria 10-K Reveals Material Weakness, $5.4M Goodwill Impairment, and Restructuring Details
NEUP sits 16% above its 52-week low of $3.19 on light trading volume (0.1× avg).
Summary
Neuphoria's 10-K reveals a material weakness in goodwill impairment controls, a $5.4M impairment charge from Merck's trial cancellation, and $1.28M in restructuring costs, while confirming cash runway beyond Q2 fiscal 2028.
Key Events · Earnings and Guidance · NEUP
-
Material Weakness in Goodwill Controls
Management identified a material weakness in internal control over financial reporting related to the evaluation of goodwill for impairment, specifically the identification of potential triggering events. This resulted in the company not timely identifying a triggering event requiring a quantitative goodwill impairment assessment.
-
$5.4M Goodwill Impairment Charge
The company recorded a $5.4 million goodwill impairment charge at June 30, 2026, after Merck announced cancellation of its Alzheimer's trial of MK-1167 on July 1, 2026. The impairment was driven by downward revisions to expected future cash flows from the Merck collaboration.
-
Restructuring Costs of $1.28M
Restructuring costs totaled $1.28 million for fiscal 2026, including $1.41 million in employee termination costs, $47,608 impairment of right-of-use asset, and $437,994 in other costs, partially offset by $618,971 in refundable credits on contract terminations.
-
ATM Facility Raised $18.5M
During fiscal 2026, the company issued 3,398,869 shares under its ATM facility, receiving gross proceeds of approximately $18.5 million. The ATM facility was increased to $20 million in November 2025 after the public float exceeded $75 million.
Analysis · NEUP · Life Sciences
This annual report discloses a material weakness in internal controls over goodwill impairment evaluation, a $5.4 million goodwill impairment charge triggered by Merck's cancellation of the MK-1167 Phase 2 trial, and $1.28 million in restructuring costs. The company also raised $18.5 million through its ATM facility during fiscal 2026, issuing 3.4 million shares. Management concluded no substantial doubt exists regarding going concern, with cash runway extending beyond Q2 fiscal 2028. These disclosures provide critical financial and governance context for the pending Scancell merger.
How filings like this one have moved
In the 30 days to Nov 12, 2026, 47.3% of the 1873 measured filings Wiseek scored 8 moved their stock by 5% or more by the next session's close. The median move was -0.17%. These are measured outcomes after filings of this importance, not a forecast for this one.
Measured one observation per ticker per day, after exclusions. Current figures: Filing Impact Tracker · open dataset
At the time of this filing, NEUP was trading at $3.70 on NASDAQ in the Life Sciences sector, with a market capitalization of approximately $20M. The 52-week trading range was $3.19 to $21.40. This filing was assessed with negative market sentiment and an importance score of 8 out of 10.